A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia

2014224 citationsJournal Articlebronze Open Access

Authors

Samir S. Awad · Baylor College of Medicine

Alejandro Rodríguez · Hospital Universitari Joan XXIII de Tarragona

Yin-Ching Chuang · Chi Mei Medical Center

Z Marjanek

A. J. Pareigis · Medical Research Associates

Gilmar Reis · Grupo Santa Casa de Belo Horizonte

Thomas Scheeren · University of Groningen

Abstract

Ceftobiprole is a safe and effective bactericidal antibiotic for the empiric treatment of HAP (excluding VAP). Further investigations are needed before recommending the use of ceftobiprole in VAP patients. Clinical Trials Registration. NCT00210964, NCT00229008.

Topics & Keywords

Pneumonia and Respiratory Infections Antibiotics Pharmacokinetics and Efficacy Antibiotic Resistance in Bacteria

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 59, Issue 1, pp. 51-61

DOI: 10.1093/cid/ciu219

Field-Weighted Citation Impact: 12.45